EHA 2023 | AML19: FLAG-Ida vs CPX-351 in patients with AML with adverse risk cytogenetics
Nigel Russell, MD, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, comments on an analysis from the AML19 trial (NCT01093514) comparing CPX-351 to FLAG-Ida-based chemotherapy in patients with adverse risk cytogenetics. Whilst the study did not show an overall survival (OS) benefit for CPX-351, there was a trend towards a benefit in relapse-free survival (RFS) in patients treated with CPX-351. In addition, patients with secondary AML genomic characteristics had superior survival outcomes with CPX-351. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding from Jazz Pharmaceuticals
